Adicet Bio financials
$6.83+7.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$22.3M | -$21.6M | -$31.9M | -$28.0M | -$32.4M | -$29.9M | -$30.7M | -$33.2M | -$32.8M | -$30.9M | -$31.6M | -$52.3M |
| Net income | -$21.4M | -$20.2M | -$30.5M | -$26.9M | -$31.2M | -$28.2M | -$28.7M | -$30.5M | -$29.9M | -$28.0M | -$29.5M | -$49.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.99 | $-1.88 | — | $-4.64 | $-5.48 | $-4.96 | $-5.06 | $-5.44 | $-5.28 | $-5.60 | $-10.90 | $-18.56 |
| EBITDA | -$21.1M | -$20.2M | -$30.4M | -$26.4M | -$30.7M | -$28.2M | -$29.1M | -$31.6M | -$31.2M | -$29.2M | -$29.9M | -$31.2M |
| Operating cash flow | -$19.8M | -$21.5M | -$20.9M | -$22.3M | -$26.6M | -$25.4M | -$24.1M | -$22.0M | -$23.4M | -$22.8M | -$23.5M | -$21.2M |
| Free cash flow | -$20.0M | -$21.5M | -$20.9M | -$22.5M | -$26.7M | -$26.9M | -$24.3M | -$22.4M | -$23.7M | -$23.1M | -$23.6M | -$22.1M |
| Diluted shares | 10.7M | 10.7M | — | 5.7M | 5.7M | 5.7M | 5.7M | 5.7M | 5.7M | 4.9M | 2.7M | 2.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.1M | $36.2M | $38.9M | $29.1M | $34.7M | $28.1M |
| Short-term investments | $85.1M | $101.3M | $119.6M | $74.0M | $90.2M | $122.3M |
| Total debt | $798.0K | $989.0K | $991.0K | $966.0K | $0.00 | $0.00 |
| Total assets | $148.2M | $169.4M | $192.4M | $140.5M | $163.0M | $191.3M |
| Total liabilities | $28.0M | $29.3M | $33.1M | $31.3M | $29.6M | $29.8M |
| Shareholders' equity | $120.1M | $140.1M | $159.2M | $109.1M | $133.4M | $161.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology